Bionano Genomics Reports Q4 and Full-Year 2025 Results, Sees Continued Growth in OGM Utilization
ByAinvest
Monday, Mar 23, 2026 4:06 pm ET1min read
BNGO--
Bionano Genomics reported Q4 2025 total revenue of $8.0 million, a 3% decrease from the same period in 2024. Consumables and software revenues decreased 1%, while gross margin increased to 43%. For the full year, total revenue decreased 7% to $28.5 million, with consumables and software revenues increasing 7%. The company reduced operating expenses by 22% and installed 9 new OGM systems, bringing its installed base to 387.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet